Picking Up the Biotech Tab | GenomeWeb

Drugs like Genentech's Herceptin show what biotech can do when it comes to innovating blockbuster treatments, says Robert Langreth on the Forbes Treatments blog. Indeed by 2014, analysts predict that the top five bestselling drugs will have come from biotech. The problem is, no one wants to pay for the next generation of treatments, like those derived from stem cells, that could be hitting the market around 2020, Langreth says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.